14871-92-2

Basic information

• Product Name: (2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II)
• Synonyms: (2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II);(2,2'-Bipyridine)dichloropalladium;2,2'-Bipyridylpalladium dichloride;Bis(2,2'-bipyridine)palladium dichloride;cis-(2,2'-Bipyridine)dichloropalladium;Dichloro(2,2'-bipyridine)palladium;Palladium,(2,2'-bipyridine-kN1,kN1')dichloro-, (SP-4-2)-;2,2′-Bipyridinepalladium dichloride
• CAS NO: 14871-92-2
• Molecular Formula: C₁₀H₈Cl₂N₂Pd
• Molecular Weight: 333.51
• Product Categories: Homogeneous Pd Catalysts;Catalysis and Inorganic Chemistry;Palladium;Pd
• Mol File: 14871-92-2.mol
• Article Data: 37

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II)(CAS DataBase Reference)
• NIST Chemistry Reference: (2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II)(14871-92-2)
• EPA Substance Registry System: (2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II)(14871-92-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 14871-92-2(Hazardous Substances Data)

Usage

General Description

(2,2'-BIPYRIDINE)DICHLOROPALLADIUM(II) is a chemical compound that consists of a palladium atom bonded to two chloride ions and two molecules of 2,2'-bipyridine. This complex is commonly used as a catalyst in various organic synthesis reactions, particularly in cross-coupling reactions. It is known for its high stability and reactivity, and it has been studied extensively for its potential applications in the pharmaceutical and materials science industries. The presence of the 2,2'-bipyridine ligands in the complex enhances the versatility and selectivity of the palladium catalyst, making it an important tool for the production of complex organic molecules.

Upstream product

• 366-18-7 [2,2]bipyridinyl 
• 7440-05-3 palladium 
• 15617-18-2 bis(benzonitrile)palladium(II) dichloride 
• 10025-98-6 potassium tetrachloropalladate(II) 
• 110173-82-5 PdCl₂(P(C₆H₅)(C₅H₄N)2)2 
• 52518-95-3 CuCl₂(C₄H₉NH₂)2 
• 13869-70-0 Ni(aniline)2Cl₂ 
• 128-09-6 N-chloro-succinimide 
• 301840-93-7 PdCl(CONCH₂CH₂OCH₂CH₂)(2,2'-dipyridine) 
• 7782-50-5 chlorine 
• 301840-91-5 PdCl(CON(CH₂)5)(2,2'-dipyridine) 
• 301840-96-0 Pd(CONCH₂CH₂OCH₂CH₂)2(2,2'-dipyridine) 
• 301840-95-9 Pd(CON(CH₂)5)2(2,2'-dipyridine) 
• 999-78-0 4,4-dimethyl-2-pentyne 

Downstream Products

• 220171-63-1 Pd((C₅H₄N)2)(N(P(O)(C₆H₅)2)P(S)(C₆H₅)2)⁽¹⁺⁾*PF₆^(1-)=[Pd((C₅H₄N)2)(N(P(O)(C₆H₅)2)P(S)(C₆H₅)2)]PF₆ 
• 220171-66-4 Pd((C₅H₄N)2)(N(P(O)(C₆H₅)2)P(Se)(C₆H₅)2)⁽¹⁺⁾*PF₆^(1-)=[Pd((C₅H₄N)2)(N(P(O)(C₆H₅)2)P(Se)(C₆H₅)2)]PF₆ 
• 113872-71-2 PdCl₂(C₆H₄OMe-p)NCHCHN(C₆H₄OMe-p) 
• 172270-26-7 [PdCl(2,2'-bipyridine)(1,4-dimethoxy-2-diphenylphosphinobenzene)][PF₆] 
• 88291-83-2 [Pd₂Cl₂(1,2,3,4-tetraphenylbuta-1,3-diene-1,4-diyl)(2,2'-bipyridine)2] 
• 7440-05-3 palladium 
• 55172-29-7 thallium chloride 
• 301840-91-5 PdCl(CON(CH₂)5)(2,2'-dipyridine) 
• 6091-44-7 piperidine hydrochloride 
• 301840-95-9 Pd(CON(CH₂)5)2(2,2'-dipyridine) 
• 275369-89-6 [(C₆F₅)2Pd(C₃H₃N₂)2Pd(C₅H₄NC₅H₄N)] 
• 457604-97-6 Pd(o-amidophenolato)(2,2-bipyridine) 
• 436154-28-8 [PdPC₆H₅(C₆H₄S)2]2 
• 175693-33-1 PdCl(2,4,6-tris(trifluoromethyl)phenyl)(2,2'-bipyridine) 

Relevant articles and documents

Multi-target heteroleptic palladium bisphosphonate complexes

Abstract: Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis and other bone illnesses. Some of them have also shown antiparasitic activity. In search of improving the pharmacological profile of commercial bisphosphona

A model study of alternative approach toward a class of palladium(II) based self-assembly

A different approach developed for the preparation of palladium(II) based complexes [(Pd(bpy))x(L)y](NO3) 2x is modelled by using 4-phenylpyridine as ligand (L = 1). Various solvent systems are inspected to opti

Synthesis, Characterization, and Cytotoxicity of Palladium(II) Complexes with Diimine/Diamine and N-Carbonyl-L-Phenylalanine Dianion

Six palladium(II) complexes, [Pd(bipy)(Bzphe-N,O)] (I-a), [Pd(bipy)(p-Mbzphe-N,O)]·2H2O (I-b), [Pd(bipy)(p-Nbzphe-N,O)]·2H2O (I-c), [Pd(phen)(Bmined by X-ray diffraction. The cytotoxicity test indicates that the complexes exert cytot

Perfluoroalkylation of Square-Planar Transition Metal Complexes: A Strategy to Assemble Them into Solid State Materials with a π-π Stacked Lamellar Structure

Formation of π-π stacked lamellar structure is important for high performance organic semiconductor materials. We previously demonstrated that perfluoroalkylation of aromatics and heteroaromatics was one of the strategies to design organic crystalline materials with π-π stacked lamellar structures while improving air stability as a result of the strong electron withdrawing ability of perfluoroalkyl substituents. Square-planar transition metal complexes with large π-conjugated ligands are also an important category of semiconductor materials. We have perfluoroalkylated square-planar transition metal complexes, leading to the formation of a π-π stacked lamellar crystal packing motif in the solid state. Here we report six crystal structures of Pd and Pt complexes with bis-perfluorobutylated catechol ligand as one of the two ligands that bonds to the metal centers. This structural design possesses similar molecular topology when compared to perfluoroalkylated aromatics and heteroaromatics we have reported previously, again, demonstrating the steering power of the perfluoroalkyl substituents in engineering organic and organometallic solid state materials.

Mixed neutral compounds of palladium(II) and platinum (II) chelated by diolato(2-) and di-imine ligands

The synthesis and characterization are described for compounds abbreviated (a) 1-5: [Pd(phen)(OO)], where OO = the dianion from 1,2-ethanediol (1), (+)-1,2-propanediol (2), (±)-2,3-butanediol (3), (-)-1,2-butanediol (4), catechol (5); (b) the sulphur analogue (6) [Pd(phen)(SCH2CH2S)], from ethane-1,2-dithiol; (c) the platinum analogue (7) [Pt(phen)(OCH2CH2O)]; (d) the 2,2′-bipyridyl analogue (8), [Pd(bipy)(OCH2CH2O)] (phen = 1,10-phenanthroline and bipy = 2,2′-bipyridyl).

Synthesis, speciation, DNA binding, electrochemical and antiproliferative properties of pd(ii) complexes designed to improve the Interaction with DNA

With the success of cisplatin, further extensive research activities resulted in the discovery of carboplatin (a second-generation drug), where the chloride is replaced by 1,1-cyclobutanedicarboxylate as a new leaving group. In the current study, we continue our previous work on the binding behavior of [Pd(byp)(H2O)2]2+ with structural features that enhance the interaction with DNA. The coordination properties of 2,2-bipyridine ligand have been changed such that a versatile ligand can be formed. [Pd(byp)(gly)]+ (1) and [Pd(byp)(CBDCA)] (2), where byp is 2,2-bipyridine, gly is glycine, and CBDCA is cyclobutane-1,1-dicarboxylic acid, were synthesized and characterized. The stability constants and stoichiometries of the complexes formed between various DNA unit constituents and [Pd(byp)(H2O)2]2+ were investigated. The binding properties of the complexes (1) and (2) with CT-DNA were analyzed by UV-vis spectroscopy, viscosity measurements, and cyclic voltammmetry. The determined binding constants for both complexes show strong binding to CT-DNA. The (Kb) values of both complexes are found to be greater than that reported in our previous finding for [Pd(byp)(H2O)2]2+. The determined (Kb) value for complex (1) (Kb= 4.36x103 M?1 ) as a cationic intercalator, suggests an electrostatic binding mode of the positively charged complex (1) together with hydrogen bonding with the negative sites of the bound DNA. The comparatively higher (Kb) value measured for complex (2) (Kb= 2.11x104 M?1) indicates an intercalation mode of binding whereby a ring-opening reaction of CBDCA occurs, followed by the reaction with guanosine 5'-monophosphate to form [(Pdbyp)(CBDCA-O)(5'-GMP)]. The small change in the measured δTm following binding of complex (1) supports strong electrostatic binding, while the significant change in δTm obtained for complex (2) supports the intercalation mode of binding. The two complexes in the absence and in the presence of CT-DNA show quasi-reversible oxidation-reduction redox CV wave . The variation in the values of E1/2, ?Ep and Ipc/Ipa also supports the electrostatic binding of the complex (1) and the intercalation mode for complex (2). The antitumor effects of the two complexes were tested against two different types of cancer cell lines, breast cancer (MCF-7) and colon cancer (HCT-116), as well as one normal cell line; the human normal melanocytes (HFB4). The two complexes display dose-dependent anti-proliferation activity. Complex (2) was shown to have more efficient apoptosis than Complex (1) and may be considered a model for carboplatin with a prediction of improved efficacy against cancer.

Palladium and platinum complexes of folic acid as new drug delivery systems for treatment of breast cancer cells

Cisplatin is administrated as an agent in treatment of various cancers by intercalation between DNA strands and inhibition of DNA replication. Among the various factors, two important reasons like inhibition of apoptosis by anti-apoptotic mechanisms and i